Literature DB >> 1696829

Isolation and characterization of human fibroblast tenascin. An extracellular matrix glycoprotein of interest for developmental studies.

Y Oike1, H Hiraiwa, H Kawakatsu, M Nishikai, T Okinaka, T Suzuki, A Okada, R Yatani, T Sakakura.   

Abstract

We have developed a biochemical method for purifying human tenascin from cultured fibroblasts or the culture medium. The method is a series of biochemical procedures including gel filtration, gelatin gel affinity chromatography and ion-exchange high performance liquid chromatography. The final preparation was identified as tenascin from its immunological cross-reactivity to antibody against chicken tenascin, strong hemagglutination activity which has been reported to be one of the biological functions of chicken tenascin, and from the electron microscopic study demonstrating a six-armed structure. Gel chromatography showed that intact human tenascin has an apparent molecular weight of over one million. Analysis of the purified tenascin with SDS-PAGE under reducing conditions demonstrated that tenascin consists of two kinds of subunits (250K and 190K). We established rat x mouse heterohybridoma cell lines which produce tenascin-specific antibodies. One monoclonal antibody (RCB1) was selected for immunohistochemical study and partially characterized. RCB1 bound native tenascin but not reduced and alkylated tenascin. Immunohistochemistry of normal and neoplastic tissues demonstrated that RCB1 bound the connective tissues surrounding the cancer nests and various normal tissues including interstitium of renal distal tubule, periosteum, endosteum, smooth muscles of digestive tract and media of arteries and arterioles.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1696829

Source DB:  PubMed          Journal:  Int J Dev Biol        ISSN: 0214-6282            Impact factor:   2.203


  15 in total

1.  The change in tenascin expression in mouse uterus during early pregnancy.

Authors:  H Kida; M Taga; H Minaguchi; M Hanazono; T Ohashi; T Sakakura; M Kusakabe
Journal:  J Assist Reprod Genet       Date:  1997-01       Impact factor: 3.412

2.  Differential expression of tenascin in the skin during hapten-induced dermatitis.

Authors:  Y Koyama; K Norose; M Kusubata; S Irie; M Kusakabe
Journal:  Histochem Cell Biol       Date:  1996-09       Impact factor: 4.304

3.  The fibrinogen globe of tenascin-C promotes basic fibroblast growth factor-induced endothelial cell elongation.

Authors:  S Schenk; R Chiquet-Ehrismann; E J Battegay
Journal:  Mol Biol Cell       Date:  1999-09       Impact factor: 4.138

4.  Tenascin expression in endomyocardial biopsy specimens in patients with dilated cardiomyopathy: distribution along margin of fibrotic lesions.

Authors:  A Tamura; S Kusachi; K Nogami; A Yamanishi; Y Kajikawa; S Hirohata; T Tsuji
Journal:  Heart       Date:  1996-03       Impact factor: 5.994

Review 5.  Tenascins, a growing family of extracellular matrix proteins.

Authors:  R Chiquet-Ehrismann
Journal:  Experientia       Date:  1995-09-29

6.  Relationship between tenascin and alpha-smooth muscle actin expression in the developing human small intestinal mucosa.

Authors:  J F Beaulieu; S Jutras; J Durand; P H Vachon; N Perreault
Journal:  Anat Embryol (Berl)       Date:  1993-08

7.  Immunohistochemical staining patterns of tenascin in invasive breast carcinomas.

Authors:  T Shoji; T Kamiya; A Tsubura; T Hatano; T Sakakura; M Yamamoto; S Morii
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

8.  Tenascin expression in normal human adult skin and skin appendage tumours.

Authors:  N Shikata; T Oyaizu; H Andachi; A Tsubura
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

9.  Tenascin in cerebrospinal fluid is a useful biomarker for the diagnosis of brain tumour.

Authors:  J Yoshida; T Wakabayashi; S Okamoto; S Kimura; K Washizu; K Kiyosawa; K Mokuno
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-10       Impact factor: 10.154

10.  Specific expression of tenascin in human colonic neoplasms.

Authors:  T Sakai; H Kawakatsu; N Hirota; T Yokoyama; T Sakakura; M Saito
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.